Sandoz Invites Young Entrepreneurs to Enter #SandozHACk, a Global Competition to Help Solve Healthcare Access Challenges

NovartisSandoz, the Novartis generic and biosimilar pharmaceutical division, announces the launch of Sandoz HACk - Healthcare Access Challenge - a global competition to generate innovative ideas and solutions to help tackle some of the world's most pressing healthcare access problems. The competition is open for entries until November 30, 2016.

"As global healthcare costs continue to rise faster than economic growth, health access will not improve without a major collaborative effort to address the gap, driven by fresh thinking," said Richard Francis, Division Head and CEO of Sandoz. "We believe that the biggest changes often come from amazing, small ideas and with the launch of Sandoz HACk we want to identify, promote and nurture creative ideas from around the world to help reimagine access to healthcare."

Despite the significant advances made in modern medicine, more than two billion people worldwide cannot access the medicines they need and more than 400 million lack access to essential health services.[1] The combined efforts of stakeholders across both public and private sectors, including the pharmaceutical industry, not-for-profit organizations and governments have made significant advances in tackling healthcare access challenges worldwide. But these large scale systemic initiatives need to be supported by community-led change, driven by innovative small scale solutions that can make a big difference. This is why Sandoz is launching Sandoz HACk, inviting people to generate novel solutions to tackle key healthcare access challenges in local communities.

Mobile technology is radically altering how care is delivered and received worldwide and the influence of mobile in healthcare is likely to continue evolving in the future. In its inaugural year, Sandoz HACk encourages today's generation of entrepreneurs and creative thinkers to enter ideas that harness mobile health technologies - M-Health - to help solve relevant local healthcare access challenges.

Sandoz HACk is open for entries from 18-35 year olds around the world. Following a robust judging process, the six finalist entries will be published on OpenIDEO - a global community of leading organizations and individuals working together to design solutions to the world's biggest challenges. Entrants' ideas will be refined and evolved in partnership with this online community before being presented to a panel of judges. Three winners will be chosen and awarded seed funding and mentorship to help bring their ideas to life.

Details of how to enter the competition and the terms and conditions can be found here:
https://www.sandoz.com/making-access-happen

Join the conversation on Twitter and Facebook using #SandozHACk.

About Sandoz
Sandoz is a global leader in generic and biosimilar pharmaceuticals. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2015 sales of USD 10.1 billion. In 2015, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

1. WHO: Health in 2015; Access to Medicine Index 2015

Most Popular Now

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Digital ECGs at Barts Health: A High-Imp…

Opinion Article by Dr Krishnaraj Sinhji Rathod, consultant in interventional cardiology, Barts Health NHS Trust. Picture the moment. A patient in an ambulance, enroute to hospital with new chest pain. Paramedics...

Study Sheds Light on Hurdles Faced in Tr…

Implementing artificial intelligence (AI) into NHS hospitals is far harder than initially anticipated, with complications around governance, contracts, data collection, harmonisation with old IT systems, finding the right AI tools...

Using Deep Learning for Precision Cancer…

Altuna Akalin and his team at the Max Delbrück Center have developed a new tool to more precisely guide cancer treatment. Described in a paper published in Nature Communications, the...

New AI Approach Paves Way for Smarter T-…

Researchers have harnessed the power of artificial intelligence (AI) to tackle one of the most complex challenges in immunology: predicting how T cells recognize and respond to specific peptide antigens...

Study Used AI Models to Improve Predicti…

Chronic kidney disease (CKD) is a complex condition marked by a gradual decline in kidney function, which can ultimately progress to end-stage renal disease (ESRD). Globally, the prevalence of the...

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...